The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension.


:Angiotensin converting enzyme (ACE) inhibitors are increasingly important in antihypertensive therapy because of their efficacy, tolerability, and specific benefits in subsets of patients. They are pharmacologically diverse. Whereas most benefits have been proven with older agents (captopril, enalopril), newer agents, such as benazepril, quinapril, and ramipril, offer potential advantages that remain to be proven.


J Clin Pharmacol


Burris JF




Has Abstract


1995-04-01 00:00:00












  • Comparison of the stability, efficacy, and adverse effect profile of the innovator 0.005% latanoprost ophthalmic solution and a novel cyclodextrin-containing formulation.

    abstract::Recently, a new latanoprost ophthalmic solution containing cyclodextrins was developed. The purpose of the present work was to compare the stability, clinical efficacy, and adverse effect profile of this formulation with the innovator product. The innovator formulation was stable at 4 degrees C but exhibited degradati...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验


    authors: Gonzalez JR,Baiza-Duran L,Quintana-Hau J,Tornero-Montaño R,Castaneda-Hernandez G,Ortiz M,Alarcon-Oceguera F,Beltran-Loustaunau M,Cortez-Gastelum M,Garcidueñas-Mejia J,Gomez-Bastar P,Jimenez-Roman J,Korder-Ortega V,Paczka-Zapata

    更新日期:2007-01-01 00:00:00

  • Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.

    abstract::The cytochromes P450 (CYPs) constitute a superfamily of hemoprotein enzymes that are responsible for the biotransformation of numerous xenobiotics, including therapeutic agents. Studies of the biochemical and enzymatic properties of these enzymes and their molecular genetics and regulation of gene expression and activ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审


    authors: Venkatakrishnan K,Von Moltke LL,Greenblatt DJ

    更新日期:2001-11-01 00:00:00

  • A pharmacological analysis of levonantradol antinociception in mice.

    abstract::Using the hot plate test, the potency and mechanism of the analgesic activity of levonantradol was studied in mice. Levonantradol is 10 to 30 times more potent than morphine; the antinociception can be only partially blocked by naloxone. Similar limited antagonism by cholinergics indicates possible opiodergic mechanis...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章


    authors: Jacob JJ,Ramabadran K,Campos-Medeiros M

    更新日期:1981-08-01 00:00:00

  • A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects.

    abstract::A single-center, double-blind, placebo-controlled, randomized study was conducted to determine the pharmacokinetics, safety, and tolerability of single, rising intramuscular (i.m.) doses and the single maximum tolerated dose of parecoxib sodium, a prodrug of the novel COX-2 selective anti-inflammatory analgesic drug v...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Karim A,Laurent A,Slater ME,Kuss ME,Qian J,Crosby-Sessoms SL,Hubbard RC

    更新日期:2001-10-01 00:00:00

  • Clinical effects of pentazocine in hospitalized medical patients.

    abstract::Of 17,068 hospitalized medical patients monitored in a drug surveillance program, 616 (3.6 per cent) received pentazocine hydrochloride orally and 816 (4.8 per cent) received pentazocine lactate parenterally during one or more admissions. Unsatisfactory analgesic efficacy as judged by each patient's physician was near...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章


    authors: Miller RR

    更新日期:1975-02-01 00:00:00

  • Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder.

    abstract::Lemborexant is a novel orexin receptor antagonist approved in the United States and Japan for the treatment of insomnia. This article describes the population pharmacokinetics (PK) of lemborexant and the relationship of its daily steady-state exposure (Cav,ss ) to the probability of most frequent treatment-emergent ad...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章


    authors: Lalovic B,Majid O,Aluri J,Landry I,Moline M,Hussein Z

    更新日期:2020-12-01 00:00:00

  • Guidelines for antiinflammatory drug research.

    abstract::Guidelines have been developed by the Bureau of Drugs, FDA, for antinflammatory drug development. They address the problem of efficacy and safety testing but leave the definition of qualified investigators and appropriate subjects unstated. The natural history of rheumatoid arthritis, the most-studied chronic inflamma...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章


    authors: Ehrlich GE

    更新日期:1977-11-01 00:00:00

  • Pharmacokinetics of esmolol in hepatic disease.

    abstract::Esmolol is an intravenous beta blocker with a short duration of action. The pharmacokinetics of esmolol and its acid metabolite, ASL-8123, were studied in nine patients who had stable, biopsy-proved Laennec's cirrhosis and in three normal volunteer controls. Kinetics were determined after a four-hour continuous infusi...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章


    authors: Buchi KN,Rollins DE,Tolman KG,Achari R,Drissel D,Hulse JD

    更新日期:1987-11-01 00:00:00

  • Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator.

    abstract::CS-0777 is a selective sphingosine 1-phosphate receptor-1 (S1P(1)) modulator under development for treatment of autoimmune conditions. A randomized, double-blind, placebo-controlled study was conducted to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CS-0777 in escalat...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验


    authors: Moberly JB,Rohatagi S,Zahir H,Hsu C,Noveck RJ,Truitt KE

    更新日期:2012-07-01 00:00:00

  • The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.

    abstract::Nateglinide (Starlix, SDZ DJN 608 or A-4166), a new insulinotropic agent, is intended to be administered prior to a meal in order to improve early insulin release in non-insulin-dependent diabetes mellitus patients. The effects of a meal on the oral bioavailability and pharmacodynamic actions of nateglinide were inves...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Karara AH,Dunning BE,McLeod JF

    更新日期:1999-02-01 00:00:00

  • Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.

    abstract::We report population pharmacokinetic, pharmacodynamic, and pharmacokinetic-safety analyses to support phase II/III dose/regimen selection of alisertib, a selective Aurora A kinase (AAK) inhibitor. Phase I studies in adult cancer patients evaluated dosing on Days 1-7 in 21-day cycles or Days 1-21 in 35-day cycles, with...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章


    authors: Venkatakrishnan K,Zhou X,Ecsedy J,Mould DR,Liu H,Danaee H,Fingert H,Kleinfield R,Milton A

    更新日期:2015-03-01 00:00:00

  • Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment.

    abstract::Evolocumab binds PCSK9, increasing low-density lipoprotein cholesterol (LDL-C) receptors and lowering LDL-C. Target-mediated evolocumab elimination is attributable to PCSK9 binding. As circulating PCSK9 and LDL-C levels are primarily regulated by the liver, we compared evolocumab pharmacokinetics, pharmacodynamics, an...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章


    authors: Gibbs JP,Slatter JG,Egbuna O,Geller M,Hamilton L,Dias CS,Xu RY,Johnson J,Wasserman SM,Emery MG

    更新日期:2017-04-01 00:00:00

  • Reduced renal clearance of oxypurinol during a 400 calorie protein-free diet.

    abstract::A decrease in dietary protein intake lowers the clearance of a number of substances excreted principally by the kidney including uric acid and oxypurinol, the major metabolite of allopurinol. We studied the kinetics of uric acid and oxypurinol in seven healthy volunteers on a normal protein diet (2600 calories; 100 g ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章


    authors: Kitt TM,Park GD,Spector R,Tsalikian E

    更新日期:1989-01-01 00:00:00

  • Development and Verification of a Body Weight-Directed Disease Trial Model for Glucose Homeostasis.

    abstract::Weight loss has been associated with improvement in insulin sensitivity. It is consequently a cornerstone in the management of type 2 diabetes mellitus (T2DM). However, the strictly quantitative relationship between weight loss, insulin sensitivity, and clinically relevant glucose homeostasis biomarkers as well as cha...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章


    authors: Farhan N,Gebert I,Xing Y,Wieser K,Lingineni K,Ma X,Chien JY,Garhyan P,Schmidt S

    更新日期:2021-02-01 00:00:00

  • The absolute bioavailability of oral melatonin.

    abstract::The absolute bioavailability of oral melatonin tablets was studied in 12 normal healthy volunteers. Subjects were administered, in a randomized crossover fashion, melatonin 2 mg intravenously and 2 and 4 mg orally. Blood was sampled over approximately eight (estimated) half-lives. Both the 2 and the 4 mg oral dosages ...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: DeMuro RL,Nafziger AN,Blask DE,Menhinick AM,Bertino JS Jr

    更新日期:2000-07-01 00:00:00

  • Dose-response studies of lormetazepam: efficacy, side effects, and rebound insomnia.

    abstract::Lormetazepam, an investigational hypnotic, was evaluated for efficacy and withdrawal phenomena in doses of 0.5, 1.0, 1.5, and 2.0 mg in four separate sleep laboratory protocols, each including four placebo baseline nights, seven drug nights, and three placebo withdrawal nights. A moderate degree of efficacy was shown ...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章


    authors: Kales A,Bixler EO,Soldatos CR,Mitsky DJ,Kales JD

    更新日期:1982-11-01 00:00:00

  • Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects.

    abstract::To explore the clinical relevance of inhibition of multidrug resistance transporter 1 and organic anion transporting polypeptide transporter, a drug-drug interaction study was conducted using aliskiren and cyclosporine. This was an open-label, single-sequence, parallel-group, single-dose study in healthy subjects. Sub...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章


    authors: Rebello S,Compain S,Feng A,Hariry S,Dieterich HA,Jarugula V

    更新日期:2011-11-01 00:00:00

  • Evaluation of butaclamol in chronic schizophrenic patients.

    abstract::In a double-blind, placebo-controlled study, an attempt was made to evaluate butaclamol in chronic schizophrenic patients using chlorpromazine (CPZ) as the standard comparative drug. With doses up to 50 mg/day, butaclamol was shown to have significant antipsychotic activity comparable to CPZ but with a much higher inc...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章


    authors: Clark ML,Paredes A,Costiloe JP,Wood F

    更新日期:1977-08-01 00:00:00

  • Viloxazine and the depressed schizophrenic--methodological issues.

    abstract::A pilot study of a small group of schizophrenic patients manifesting symptoms of a depressive nature was treated in a double-blind study in which viloxazine or a placebo was administered in combination with either chlorpromazine or haloperidol. There appeared to be no difference between the viloxazine-treated group an...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章


    authors: Kurland AA,Nagaraju A

    更新日期:1981-01-01 00:00:00

  • The effects of five potassium chloride preparations on the upper gastrointestinal mucosa in healthy subjects receiving glycopyrrolate.

    abstract::The effects on the upper gastrointestinal tract of five different preparations of KCl were compared in 90 healthy subjects treated with glycopyrrolate. The KCl preparations studied were wax-matrix KCl, microencapsulated KCl, liquid KCl, experimental extended-release capsules, experimental extended-release tablets,and ...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章


    authors: Alsop WR,Moore JG,Rollins DE,Tolman KG

    更新日期:1984-05-01 00:00:00

  • Midazolam disposition in patients undergoing continuous venovenous hemodialysis.

    abstract::The aim of the study was to investigate the pharmacokinetics and removal of midazolam and unconjugated and glucuronidated 1-hydroxy-midazolam in 4 intensive care patients on continuous venovenous hemodialysis. Plasma midazolam and its metabolites were assessed by HPLC from blood samples collected during continuous inf...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章


    authors: Bolon M,Bastien O,Flamens C,Paulus S,Boulieu R

    更新日期:2001-09-01 00:00:00

  • Effect of meals on the kinetics of etretinate.

    abstract::Eight healthy men received 100 mg oral doses of etretinate separated by two-week washout periods in an open, randomized, crossover study. Etretinate was administered during a complete fast, with a standard high fat breakfast, a standard high carbohydrate breakfast, and 16 ounces of whole milk. Plasma samples were obta...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Colburn WA,Gibson DM,Rodriguez LC,Buggé CJ,Blumenthal HP

    更新日期:1985-11-01 00:00:00

  • Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes.

    abstract::Data from five randomized, placebo-controlled, multiple oral dose studies of empagliflozin in patients with type 2 diabetes mellitus (T2DM; N = 974; 1-100 mg q.d.; ≤12 weeks) were used to develop a population pharmacokinetic (PK) model for empagliflozin. The model consisted of two-compartmental disposition, lagged fir...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验


    authors: Riggs MM,Staab A,Seman L,MacGregor TR,Bergsma TT,Gastonguay MR,Macha S

    更新日期:2013-10-01 00:00:00

  • Comparative effects of dopaminergic agonists on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients.

    abstract::The role of dopaminergic receptors on renal function has been extensively studied. Recently dopaminergic receptor has been classified in two subtypes D1 and D2, which seem to have different modulatory function. However, the role of dopaminergic receptors on cardiovascular function and more specifically the potential r...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章


    authors: Luchsinger A,Velasco M,Urbina A,Morillo J,Romero E,Alvarez R,Pieretti OH

    更新日期:1992-01-01 00:00:00

  • Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets.

    abstract::The effect of hepatic impairment on the pharmacokinetics of a sustained-release formulation of ranolazine and 3 major metabolites was investigated in an open-label, parallel-group study. Ranolazine (875-mg loading dose followed by 500 mg every 12 hours for a total of 4 maintenance doses) was administered to subjects w...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章


    authors: Abdallah H,Jerling M

    更新日期:2005-07-01 00:00:00

  • Administration of H1 and H2 antagonists for chemoprophylaxis: a double-blind, placebo-controlled study in healthy volunteers.

    abstract::A double-blind, placebo-controlled trial was performed to establish the duration of action of antihistamines and their ability to attenuate the adverse affects associated with histamine release. Thirty volunteers were assigned randomly to receive either placebo or a combination of the H1 blocker dimetindene maleate (0...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Doenicke A,Moss J,Toledano A,Hoernecke R,Lorenz W,Ostwald P

    更新日期:1997-02-01 00:00:00

  • Contrasting effects of pyrazinoylguanidine and hydrochlorothiazide in patients with renal insufficiency.

    abstract::A single blind crossover study with washout phases showed that pyrazinoylguanidine (PZG) reduced elevated serum concentrations of urea, triglycerides, and cholesterol in patients with renal insufficiency. Pyrazinoylguanidine was saluretic, without affecting serum potassium or glucose concentrations. The onset of PZG's...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章


    authors: Beyer KH Jr,Ward TD,Vary JE,Gelarden RT,Knutson DW,Vesell ES

    更新日期:1993-06-01 00:00:00

  • Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.

    abstract::Atazanavir, a potent protease inhibitor of human immunodeficiency virus (HIV), exhibits pH-dependent solubility. Previous studies have indicated that coadministration with omeprazole 40 mg once daily significantly decreased atazanavir exposure by approximately 75%. Concomitant use of omeprazole and atazanavir is curre...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验


    authors: Zhu L,Persson A,Mahnke L,Eley T,Li T,Xu X,Agarwala S,Dragone J,Bertz R

    更新日期:2011-03-01 00:00:00

  • Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects.

    abstract::This open-label, crossover study had two objectives: to compare the steady-state pharmacokinetics of high-dose telmisartan with and without coadministered high-dose hydrochlorothiazide and to compare the steady-state pharmacokinetics of hydrochlorothiazide with and without coadministered telmisartan. A total of 13 hea...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Young CL,Dias VC,Stangier J

    更新日期:2000-12-01 00:00:00

  • Application of Individualized PBPK Modeling of Rate Data (iPBPK-R) to Evaluate the Effect of Hemodialysis On Nonrenal Clearance Pathways.

    abstract::The aim of this study was to apply individualized, physiologically-based pharmacokinetic (iPBPK-R) modeling of 14 CO2 production rates measured by the erythromycin breath test (ERMBT) to characterize the effect of hemodialysis on the function of nonrenal clearance pathways in patients with end-stage renal disease (ESR...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章


    authors: Franchetti Y,Nolin TD

    更新日期:2021-01-18 00:00:00